Paul G. Richardson, MBBS

Publications

• Singh AV, Bandi M, Raje N, Richardson P, Palladino MA, Chauhan D, Anderson KC.A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells.Blood. 2011 Mar 31.
  21454451
• Dimopoulos MA, Mitsiades CS, Anderson KC, Richardson PG.Tanespimycin as antitumor therapy.Clin Lymphoma Myeloma Leuk. 2011 Feb 1;11(1):17-22.
  21454186
• Delforge M, Terpos E, Richardson PG, Shpilberg O, Khuageva NK, Schlag R, Dimopoulos MA, Kropff M, Spicka I, Petrucci MT, Samoilova OS, Mateos MV, Magen-Nativ H, Goldschmidt H, Esseltine DL, Ricci DS, Liu K, Deraedt W, Cakana A, van de Velde H, San Miguel
  21366694
• Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Bladé J, Sezer O, Ludwig H, Dimopoulos MA, Attal M, Sonneveld P, Boccadoro M, Anderson KC, Richardson PG, Bensinger W, Johnsen H, Kroeger N, Gahrton G, Bergsagel PL, Vesole DH, Einsele H, Jagannath S,
  21447828
• Laubach J, Richardson PG, Anderson K.Hematology: Setting the standard for newly diagnosed multiple myeloma.Nat Rev Clin Oncol. 2011 Mar 22.
  21423257
• Lonial S, Mitsiades CS, Richardson PG.Treatment options for relapsed and refractory multiple myeloma.Clin Cancer Res. 2011 Mar 15;17(6):1264-77.
  21411442
• Ghobrial IM, Weller E, Vij R, Munshi NC, Banwait R, Bagshaw M, Schlossman R, Leduc R, Chuma S, Kunsman J, Laubach J, Jakubowiak AJ, Maiso P, Roccaro A, Armand P, Dollard A, Warren D, Harris B, Poon T, Sam A, Rodig S, Anderson KC, Richardson PG.Weekly bort
  21345726
• Rajpal R, Dowling P, Meiller J, Clarke C, Murphy WG, O'Connor R, Kell M, Mitsiades C, Richardson P, Anderson KC, Clynes M, O'Gorman P.A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multi
  21365752
• Laubach JP, Schlossman RL, Mitsiades CS, Anderson KC, Richardson PG.Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.Expert Rev Hematol. 2011 Feb;4(1):51-60.
  21322778
• Jakubikova J, Adamia S, Kost-Alimova M, Klippel S, Cervi D, Daley JF, Cholujova D, Kong SY, Leiba M, Blotta S, Ooi M, Delmore J, Laubach J, Richardson PG, Sedlak J, Anderson KC, Mitsiades CS.Lenalidomide targets clonogenic side population in multiple myel
  21321360
• Uljon SN, Richardson PG, Schur PH, Anderson KC, Tanasijevic MJ, Lindeman NI.Serial serum free light chain measurements do not detect changes in disease status earlier than electrophoretic M-spike measurements in patients with intact immunoglobulin myeloma
  21144845
• Favis R, Sun Y, van de Velde H, Broderick E, Levey L, Meyers M, Mulligan G, Harousseau JL, Richardson PG, Ricci DS.Genetic variation associated with bortezomib-induced peripheral neuropathy.Pharmacogenet Genomics. 2011 Mar;21(3):121-9.
  21228734
• Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, Blade J, Richardson P, Orlowski R, Siegel D, Jagannath S, Facon T, Avet-Loiseau H, Lonial S, Palumbo A, Zonder J, Ludwig H, Vesole D, Sezer O, Munshi NC, San Miguel J.Consensus recomm
  21292775
• Richardson PG, Mitsiades CS, Laubach JP, Lonial S, Chanan-Khan AA, Anderson KC.Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers.British Journal of Haematology. 2011 Feb;152(4):367-79. Rev
  21219297
• McMillin DW, Delmore J, Negri J, Buon L, Jacobs HM, Laubach J, Jakubikova J, Ooi M, Hayden P, Schlossman R, Munshi NC, Lengauer C, Richardson PG, Anderson KC, Mitsiades CS.Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition
  21223249
• Rosenblatt J, Vasir B, Uhl L, Blotta S, Macnamara C, Somaiya P, Wu Z, Joyce R, Levine JD, Dombagoda D, Yuan YE, Francoeur K, Fitzgerald D, Richardson P, Weller E, Anderson K, Kufe D, Munshi N, Avigan D.Vaccination with dendritic cell/tumor fusion cells re
  21030562
• Richardson PG.A new standard of care in newly diagnosed multiple myeloma.Lancet. 2010 Dec 18;376(9758):2043-4.
  21146204
• Dimopoulos MA, Mateos MV, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, Kropff M, Spicka I, Palumbo A, Wu KL, Esseltine DL, Liu K, Deraedt W, Cakana A, Van De Velde H, San Miguel JF.Risk factors for, and reversibility of, peripheral neuropathy associ
  20874823
• Chauhan D, Singh AV, Aujay M, Kirk CJ, Bandi M, Ciccarelli B, Raje N, Richardson P, Anderson KC.A novel orally active proteasome inhibitor ONX 0912 trigger in vitro and in vivo cytotoxicity in multiple myeloma.Blood. 2010 Dec 2;116(23):4906-15.
  20805366
• Richardson PG.Improving the therapeutic index in myeloma.Blood. 2010 Dec 2;116(23):4733-4.
  21127178
• Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, Niesvizky R, Giralt S, Fermand JP, Bladé J, Comenzo RL, Sezer O, Palumbo A, Harousseau JL, Richardson PG, Barlogie B, Anderson KC, Sonneveld P, Tosi P, Rajkumar SV, Durie BG, San Mig
  20956629
• Harousseau JL, Palumbo A, Richardson PG, Schlag R, Dimopoulos MA, Shpilberg O, Kropff M, Kentos A, Cavo M, Golenkov A, Komarnicki M, Mateos MV, Esseltine DL, Cakana A, Liu K, Deraedt W, van de Velde H, San Miguel JF.Superior outcomes associated with compl
  20628153
• Richardson PG.Towards a better understanding of treatment-related peripheral neuropathy in multiple myeloma.Lancet Oncol. 2010 Nov;11(11):1014-6.
  21051016
• Görgün G, Calabrese E, Soydan E, Hideshima T, Perrone G, Bandi M, Cirstea D, Santo L, Hu Y, Tai YT, Nahar S, Mimura N, Fabre C, Raje N, Munshi N, Richardson P, Anderson KC.Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor
  20651070
• Ghobrial IM, Xie W, Padmanabhan S, Badros A, Rourke M, Leduc R, Chuma S, Kunsman J, Warren D, Poon T, Harris B, Sam A, Anderson KC, Richardson PG, Treon SP, Weller E, Matous J.Phase II trial of weekly bortezomib in combination with rituximab in untreated
  20652865
• Heher EC, Goes NB, Spitzer TR, Raje NS, Humphreys BD, Anderson KC, Richardson PG.Kidney disease associated with plasma cell dyscrasias.Blood. 2010 Sep 2;116(9):1397-404. Review.
  20462963
• Ikeda H, Hideshima T, Fulciniti M, Perrone G, Mimura N, Yasui H, Okawa Y, Kiziltepe T, Santo L, Vallet S, Cirstea D, Calabrese E, Gorgun G, Raje NS, Richardson P, Munshi NC, Lannutti BJ, Puri KD, Giese NA, Anderson KC.PI3K/p110{delta} is a novel therapeut
  20505158
• Richardson PG, Badros AZ, Jagannath S, Tarantolo S, Wolf JL, Albitar M, Berman D, Messina M, Anderson KC.Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.British Journal of Haematology. 2010 Aug;150(4):428-37.
  20618338
• Richardson PG, Chanan-Khan AA, Alsina M, Albitar M, Berman D, Messina M, Mitsiades CS, Anderson KC.Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study.British Journal of Haematology. 2010 Aug;150(4):438-45.
  20618337
• Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, Avigan DE, Xie W, Ghobrial IM, Schlossman RL, Mazumder A, Munshi NC, Vesole DH, Joyce R, Kaufman JL, Doss D, Warren DL, Lunde LE, Kaster S, Delaney C, Hideshima T, Mitsiades CS, Knigh
  20385792
• Richardson PG, Soiffer RJ, Antin JH, Uno H, Jin Z, Kurtzberg J, Martin PL, Steinbach G, Murray KF, Vogelsang GB, Chen AR, Krishnan A, Kernan NA, Avigan DE, Spitzer TR, Shulman HM, Di Salvo DN, Revta C, Warren D, Momtaz P, Bradwin G, Wei LJ, Iacobelli M, M
  20167278
• Rickles RJ, Pierce LT, Giordano TP, Tam WF, McMillin DW, Delmore J, Laubach JP, Borisy AA, Richardson PG, Lee MS.Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multi-target mechanism discovered through systematic combination screening i
  20382846
• Cutler C, Kim HT, Ayanian S, Bradwin G, Revta C, Aldridge J, Ho V, Alyea E, Koreth J, Armand P, Soiffer R, Ritz J, Richardson PG, Antin JH.Prediction Of Veno-Occlusive Disease Using Biomarkers Of Endothelial Injury.Biol Blood Marrow Transplant. 2010 Aug;1
  20184961
• Prabhala RH, Pelluru D, Fulciniti M, Prabhala HK, Nanjappa P, Song W, Pai C, Amin S, Tai YT, Richardson PG, Ghobrial IM, Treon SP, Daley JF, Anderson KC, Kutok JL, Munshi NC.Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits i
  20395418
• Laubach JP, Richardson PG, Anderson KC.The evolution and impact of therapy in multiple myeloma.Med Oncol. 2010 Jun;27 Suppl 1:S1-6. Review.
  20169425
• Mateos MV, Cibeira MT, Richardson PG, Prosper F, Oriol A, de la Rubia J, Lahuerta JJ, García-Sanz R, Extremera S, Szyldergemajn S, Corrado C, Singer H, Mitsiades CS, Anderson KC, Bladé J, San Miguel J.Phase II clinical and pharmacokinetic study of pliti
  20530693
• Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, Kröger N, Einsele H, Vesole DH, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajek R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson PG, Barlogie B, Greipp P,
  20410922
• Richardson PG, Laubach J, Mitsiades C, Schlossman RL, Doss D, Colson K, McKenney ML, Noonan K, Warren DL, Ghobrial IM, Munshi NC, Anderson K.Tailoring treatment for multiple myeloma patients with relapsed and refractory disease.Oncology (Huntingt). 2010 M
  20518367
• Echart CL, Graziadio B, Somaini S, Ferro LI, Richardson PG, Fareed J, Iacobelli M.The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity.Blood Coagul Fibrinolysis. 2009 Dec;20(8):627-34.
  19809307
• Hideshima T, Mitsiades C, Ikeda H, Chauhan D, Raje N, Gorgun G, Hideshima H, Munshi NC, Richardson PG, Carrasco DR, Anderson KC.A proto-oncogene Bcl-6 is upregulated in the bone marrow microenvironment in multiple myeloma cells.Blood. 2010 May 6;115(18):3
  20228272
• Kim K, Kong SY, Fulciniti M, Li X, Song W, Nahar S, Burger P, Rumizen MJ, Podar K, Chauhan D, Hideshima T, Munshi NC, Richardson P, Clark A, Ogden J, Goutopoulos A, Rastelli L, Anderson KC, Tai YT.Blockade of the MEK/ERK signalling cascade by AS703026, a
  20331454
• Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Esseltine DL, Liu K, Cakana A, van de Velde H, San Miguel JF.Bortezomi
  20368561
• McMillin DW, Delmore J, Weisberg E, Negri JM, Geer DC, Klippel S, Mitsiades N, Schlossman RL, Munshi NC, Kung AL, Griffin JD, Richardson PG, Anderson KC, Mitsiades CS.Tumor cell-specific bioluminescence platform to identify stroma-induced changes to antic
  20228816
• Marks LB, Cirrincione C, Fitzgerald TJ, Laurie F, Glicksman AS, Vredenburgh J, Prosnitz LR, Shpall EJ, Crump M, Richardson PG, Schuster MW, Ma J, Peterson BL, Norton L, Seagren S, Craig Henderson I, Hurd DD, Peters WP, .Impact of High-Dose Chemotherapy o
  19747781
• Ghobrial IM, Gertz M, Laplant B, Camoriano J, Hayman S, Lacy M, Chuma S, Harris B, Leduc R, Rourke M, Ansell SM, Deangelo D, Dispenzieri A, Bergsagel L, Reeder C, Anderson KC, Richardson PG, Treon SP, Witzig TE.Phase II trial of the oral mammalian target
  20142598
• Ghobrial IM, Hong F, Padmanabhan S, Badros A, Rourke M, Leduc R, Chuma S, Kunsman J, Warren D, Harris B, Sam A, Anderson KC, Richardson PG, Treon SP, Weller E, Matous J.Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relap
  20142586
• Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, Guinan E, Vogelsang G, Krishnan A, Giralt S, Revta C, Carreau NA, Iacobelli M, Carreras E, Ruutu T, Barbui T, Antin JH, Niederwieser D.Hepatic veno-occlusive disease following stem cell t
  19766729
• Richardson PG, Laubach JP, Schlossman RL, Mitsiades C, Anderson K.Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia.J Natl Compr Canc Netw. 2010 Feb;8 Suppl 1:S4-S12.
  20141673
• Ghobrial IM, Roccaro A, Hong F, Weller E, Rubin N, Leduc R, Rourke M, Chuma S, Sacco A, Jia X, Azab F, Azab AK, Rodig S, Warren D, Harris B, Varticovski L, Sportelli P, Leleu X, Anderson KC, Richardson PG.Clinical and translational studies of a phase II t
  20103671
• Fonseca R, Richardson P, Giralt S, Lonial S, Rajkumar SV, Stewart AK, Bensinger W, Somlo G, Vescio R, Mikhael J, Reeder C, Tiedemann R, Tricot G, Rifkin R, Shaughnessy J, Munshi N, Raje N, Ghobrial I, Laubach J, Schlossman R, Treon S, Mahindra A, Avigan D
  20118399
• Chauhan D, Singh AV, Ciccarelli B, Richardson PG, Palladino MA, Anderson KC.Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma.Blood. 2010 Jan 28;115(4):834-45.
  19965674
• Stewart AK, Richardson PG, San-Miguel JF.How I treat multiple myeloma in younger patients.Blood. 2009 Dec 24;114(27):5436-43.
  19861683
• Laubach JP, Mahindra A, Mitsiades CS, Schlossman RL, Munshi NC, Ghobrial IM, Carreau N, Hideshima T, Anderson KC, Richardson PG.The use of novel agents in the treatment of relapsed and refractory multiple myeloma.Leukemia..
• Dimopoulos MA, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, Kastritis E, Kropff M, Petrucci MT, Delforge M, Alexeeva J, Schots R, Masszi T, Mateos MV, Deraedt W, Liu K, Cakana A, van de Velde H, San Miguel JF.VMP (Bortezomib, Melphalan, and Predniso
  19858394
• Ooi MG, Hayden PJ, Kotoula V, McMillin DW, Charalambous E, Daskalaki E, Raje NS, Munshi NC, Chauhan D, Hideshima T, Buon L, Clynes M, O'Gorman P, Richardson PG, Mitsiades CS, Anderson KC, Mitsiades N.Interactions of the Hdm2/p53 and proteasome pathway
  19934289
• Richardson PG, Weller E, Jagannath S, Avigan DE, Alsina M, Schlossman RL, Mazumder A, Munshi NC, Ghobrial IM, Doss D, Warren DL, Lunde LE, McKenney M, Delaney C, Mitsiades CS, Hideshima T, Dalton W, Knight R, Esseltine DL, Anderson KC.Multicenter, phase I
  19786667
• Negri JM, McMillin DW, Delmore J, Mitsiades N, Hayden P, Klippel S, Hideshima T, Chauhan D, Munshi NC, Buser CA, Pollard J, Richardson PG, Anderson KC, Mitsiades CS.In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465.British Journal of Ha
  19751238
• Laubach JP, Mitsiades CS, Mahindra A, Schlossman RL, Hideshima T, Chauhan D, Carreau NA, Ghobrial IM, Raje N, Munshi NC, Anderson KC, Richardson PG.Novel therapies in the treatment of multiple myeloma.J Natl Compr Canc Netw. 2009 Oct;7(9):947-60. Review.
  19878638
• Vogl DT, Stadtmauer EA, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Facon T, Harousseau JL, Boral A, Neuwirth R, Anderson KC.Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refra
  19725827
• Laubach JP, Mitsiades CS, Mahindra A, Schlossman RL, Hideshima T, Chauhan D, Carreau NA, Ghobrial IM, Raje N, Munshi NC, Anderson KC, Richardson PG.Novel therapies in the treatment of multiple myeloma.J Natl Compr Canc Netw..
• Chauhan D, Singh AV, Brahmandam M, Carrasco R, Bandi M, Hideshima T, Bianchi G, Podar K, Tai YT, Mitsiades C, Raje N, Jaye DL, Kumar SK, Richardson P, Munshi N, Anderson KC.Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells
  19800576
• Laubach JP, Richardson PG, Anderson KC.Hematology: Thalidomide maintenance in multiple myeloma.Nat Rev Clin Oncol. 2009 Oct;6(10):565-6.
  19787000
• Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Lentzsch S, Munshi N, Niesvizky R, San Miguel J, Ludwig H, Bergsagel L, Blade J, Lonial S, Anderson KC, Tosi P, Sonneveld P, Sezer O, Vesole D, Cavo M, Einsele H, Richard
  19561323
• Chauhan D, Singh AV, Brahmandam M, Carrasco R, Bandi M, Podar K, Hideshima T, Bianchi G, Mitsiades C, Raje N, Tai Y-T, Jaye DL, Kumar SK, Schlossman R, Richardson P, Munshi N, Anderson KC.Functional Interaction of plasmacytoid dendritic cells with multipl
• Hideshima T,Ikeda H,Chauhan D,Okawa Y,Raje N,Podar K,Mitsiades C,Munshi NC,Richardson PG,Carrasco RD,Anderson KC.Bortezomib induces canonical NF-{kappa}B activation in multiple myeloma cells.Blood. 2009 Jul 30;114(5):1046-52.
  19436050
• Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC.Multiple myeloma.Lancet. 2009 Jul 25;374(9686):324-39. Review.
  19541364
• Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, Hassoun H, Avigan DE, Oaklander AL, Kuter DJ, Wen PY, Kesari S, Briemberg HR, Schlossman RL, Munshi NC, Heffner LT, Doss D, Esseltine DL, Weller E, Anderson KC, Amato AA.Single-agent bortezomib
  19528374
• McMillin DW, Ooi M, Delmore J, Negri J, Hayden P, Mitsiades N, Jakubikova J, Maira SM, Garcia-Echeverria C, Schlossman R, Munshi NC, Richardson PG, Anderson KC, Mitsiades CS.Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinas
  19584292
• Ikeda H, Hideshima T, Fulciniti M, Lutz RJ, Yasui H, Okawa Y, Kiziltepe T, Vallet S, Pozzi S, Santo L, Perrone G, Tai YT, Cirstea D, Raje NS, Uherek C, Dälken B, Aigner S, Osterroth F, Munshi N, Richardson P, Anderson KC.The monoclonal antibody nBT062 co
  19509164
• Laubach JP,Mitsiades CS,Roccaro AM,Ghobrial IM,Anderson KC,Richardson PG.Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenstroms Macroglobulinemia.Leuk Lymphoma. 2009 May;50(5):694-702. Review.
  19452315
• Mitsiades CS,Hideshima T,Chauhan D,McMillin DW,Klippel S,Laubach JP,Munshi NC,Anderson KC,Richardson PG.Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.Semin Hematol. 2009 Apr;46(2):166-75. Review.
  19389500
• Hideshima T,Chauhan D,Kiziltepe T,Ikeda H,Okawa Y,Podar K,Raje N,Protopopov A,Munshi NC,Richardson PG,Carrasco RD,Anderson KC.Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications.Blood. 2009 May 21;113(21):5
  19270264
• Podar K,Tai YT,Hideshima T,Vallet S,Richardson PG,Anderson KC.Emerging therapies for multiple myeloma.Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. Review.
  19249983
• Mitsiades CS,Rouleau C,Echart C,Menon K,Teicher B,Distaso M,Palumbo A,Boccadoro M,Anderson KC,Iacobelli M,Richardson PG.Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias.Clin Cancer Res. 2009 Feb 15;1
  19228727
• Richardson PG,Sonneveld P,Schuster MW,Stadtmauer EA,Facon T,Harousseau JL,Ben-Yehuda D,Lonial S,Goldschmidt H,Reece D,Blade J,Boccadoro M,Cavenagh JD,Boral AL,Esseltine DL,Wen PY,Amato AA,Anderson KC,San Miguel J.Reversibility of symptomatic peripheral ne
  19170677
• Wolf J,Richardson PG,Schuster M,LeBlanc A,Walters IB,Battleman DS.Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series.Clin Adv Hematol Oncol. 2008 Oct;6(10):755-60.
  18997666
• Lee SJ,Richardson PG,Sonneveld P,Schuster MW,Irwin D,San Miguel JF,Crawford B,Massaro J,Dhawan R,Gupta S,Anderson KC.Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myelom
  18986387
• Jagannath S,Barlogie B,Berenson JR,Siegel DS,Irwin D,Richardson PG,Niesvizky R,Alexanian R,Limentani SA,Alsina M,Esseltine DL,Anderson KC.Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed
  18783399
• Cutler C,Stevenson K,Kim HT,Richardson P,Ho VT,Linden E,Revta C,Ebert R,Warren D,Choi S,Koreth J,Armand P,Alyea E,Carter S,Horowitz M,Antin JH,Soiffer R.Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem c
  18776081
• San Miguel JF,Schlag R,Khuageva NK,Dimopoulos MA,Shpilberg O,Kropff M,Spicka I,Petrucci MT,Palumbo A,Samoilova OS,Dmoszynska A,Abdulkadyrov KM,Schots R,Jiang B,Mateos MV,Anderson KC,Esseltine DL,Liu K,Cakana A,van de Velde H,Richardson PG.Bortezomib plus
  18753647
• Lonial S,Richardson PG,San Miguel J,Sonneveld P,Schuster MW,Blade J,Cavenagh J,Rajkumar SV,Jakubowiak AJ,Esseltine DL,Anderson KC,Harousseau JL.Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients w
  18713253
• Chanan-Khan A,Sonneveld P,Schuster MW,Stadtmauer EA,Facon T,Harousseau JL,Ben-Yehuda D,Lonial S,Goldschmidt H,Reece D,Neuwirth R,Anderson KC,Richardson PG.Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.J Cli
  18711175
• Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P, Lee AI, Podar K, Hideshima T, Rice AG, van Abbema A, Jesaitis L, Caras I, Law D, Weler E, Xie W, Richardson P, Munshi NC, Mathiot C, Avet-Loiseau H, Afar DE, Anderson KC.Anti-CS1 humanized monoclonal ant
  17906076
• Niesvizky R,Richardson PG,Rajkumar SV,Coleman M,Rosinol L,Sonneveld P,Schuster MW,Irwin D,Stadtmauer EA,Facon T,Harousseau JL,Boral AL,Esseltine DL,Anderson KC,Blade J.The relationship between quality of response and clinical benefit for patients treated
  18673366
• Mitsiades CS,Ocio EM,Pandiella A,Maiso P,Gajate C,Garayoa M,Vilanova D,Montero JC,Mitsiades N,McMullan CJ,Munshi NC,Hideshima T,Chauhan D,Aviles P,Otero G,Faircloth G,Mateos MV,Richardson PG,Mollinedo F,San-Miguel JF,Anderson KC.Aplidin, a marine organism
  18593922
• Richardson PG,Mitsiades C,Schlossman R,Ghobrial I,Hideshima T,Munshi N,Anderson KC.Bortezomib in the front-line treatment of multiple myeloma.Expert Rev Anticancer Ther. 2008 Jul;8(7):1053-72. Review.
  18588451
• Munshi NC,Mitsiades C,Richardson PG,Anderson KC.Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma.Nat Clin Pract Oncol. 2008 Jul;5(7):374-5.
  18542118
• Treister NS, Richardson P, Schlossman R, Miller K, Woo SB.Painful tongue ulcerations in patients with bisphosphonate-associated osteonecrosis of the jaws.Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Jun;105(6):e1-4.
  18417376
• Okawa Y, Hideshima T, Ikeda H, Raje N, Vallet S, Kiziltepe T, Yasui H, Enatsu S, Pozzi S, Breitkreutz I, Cirstea D, Santo L, Richardson P, Anderson KC.Fatty acid synthase is a novel therapeutic target in multiple myeloma.British Journal of Haematology. 20
  18410446
• Richardson PG.The myeloma landscape in 2008.Clin Adv Hematol Oncol. 2008 Feb;6(2 Suppl 2):1-12; quiz 15-6.
  18347555
• Raje N, Woo SB, Hande K, Yap JT, Richardson PG, Vallet S, Treister N, Hideshima T, Sheehy N, Chhetri S, Connell B, Xie W, Tai YT, Szot-Barnes A, Tian M, Schlossman RL, Weller E, Munshi NC, Van Den Abbeele AD, Anderson KC.Clinical, radiographic, and bioche
  18413829
• Richardson PG, Niesvizky R, Anderson KC, Blade J.Re: When you look matters: the effect of assessment schedule on progression-free survival.Journal of the National Cancer Institute. 2008 Mar 5;100(5):373.
  18314478
• Richardson P, Mitsiades C, Colson K, Reilly E, McBride L, Chiao J, Sun L, Ricker J, Rizvi S, Oerth C, Atkins B, Fearen I, Anderson K, Siegel D.Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myel
  18297527
• Huston A, Leleu X, Jia X, Moreau AS, Ngo HT, Runnels J, Anderson J, Alsayed Y, Roccaro A, Vallet S, Hatjiharissi E, Tai YT, Sportelli P, Munshi N, Richardson P, Hideshima T, Roodman DG, Anderson KC, Ghobrial IM.Targeting Akt and heat shock protein 90 prod
  18245550
• Kettler GC, Martiny AC, Huang K, Zucker J, Coleman ML, Rodrigue S, Chen F, Lapidus A, Ferriera S, Johnson J, Steglich C, Church GM, Richardson P, Chisholm SW.Patterns and implications of gene gain and loss in the evolution of Prochlorococcus.PLoS Genet. 2
  18159947
• Mitsiades CS, Hayden PJ, Anderson KC, Richardson PG.From the bench to the bedside: emerging new treatments in multiple myeloma.Best Pract Res Clin Haematol. 2007 Dec;20(4):797-816. Review.
  18070720
• Podar K, Richardson PG, Hideshima T, Chauhan D, Anderson KC.The malignant clone and the bone-marrow environment.Best Pract Res Clin Haematol. 2007 Dec;20(4):597-612. Review.
  18070708
• Chauhan D, Singh A, Brahmandam M, Podar K, Hideshima T, Richardson P, Munshi N, Palladino MA, Anderson KC.Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma.Blood. 2008 Feb 1;111(3):16
  18006697
• Kastritis E, Mitsiades CS, Dimopoulos MA, Richardson PG.Management of relapsed and relapsed refractory myeloma.Hematol Oncol Clin North Am. 2007 Dec;21(6):1175-215, x. Review.
  17996594
• Mitsiades CS, McMillin DW, Klippel S, Hideshima T, Chauhan D, Richardson PG, Munshi NC, Anderson KC.The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies.Hematol
  17996586
• Rajkumar SV, Richardson PG, Lacy MQ, Dispenzieri A, Greipp PR, Witzig TE, Schlossman R, Sidor CF, Anderson KC, Gertz MA.Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma.Clin Cancer Res. 2007 Oct 15;13(
  17947482
• Hayden PJ, Mitsiades CS, Anderson KC, Richardson PG.Novel therapies in myeloma.Curr Opin Hematol. 2007 Nov;14(6):609-15. Review.
  17898564
• Breitkreutz I, Raab MS, Vallet S, Hideshima T, Raje N, Chauhan D, Munshi NC, Richardson PG, Anderson KC.Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma.British Journal of Haematology. 2007 Oct;139(1)
  17854307
• Hideshima T, Catley L, Raje N, Chauhan D, Podar K, Mitsiades C, Tai YT, Vallet S, Kiziltepe T, Ocio E, Ikeda H, Okawa Y, Hideshima H, Munshi NC, Yasui H, Richardson PG, Anderson KC.Inhibition of Akt induces significant downregulation of survivin and cytot
  17760810
• Tai YT, Fulciniti M, Hideshima T, Song W, Leiba M, Li XF, Rumizen M, Burger P, Morrison A, Podar K, Chauhan D, Tassone P, Richardson P, Munshi NC, Ghobrial I, Anderson KC.Targeting MEK induces myeloma cell cytotoxicity and inhibits osteoclastogenesis.Bloo
  17510321
• Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC.Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.Nat Rev Cancer. 2007 Aug;7(8):585-98. Review.
  17646864
• Munshi NC, Mitsiades CS, Richardson PG, Anderson KC.Does maintenance therapy with thalidomide benefit patients with multiple myeloma?.Nat Clin Pract Oncol. 2007 Jul;4(7):394-5.
  17534287
• Ho VT, Linden E, Revta C, Richardson PG.Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: review and update on the use of defibrotide.Semin Thromb Hemost. 2007 Jun;33(4):373-88. Review.
  17525895
• Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, San Miguel JF, Cavenagh JD, Anderson KC.Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.Bri
  17451408
• Podar K, Richardson PG, Chauhan D, Anderson KC.Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma.Expert Rev Anticancer Ther. 2007 Apr;7(4):551-66. Review.
  17428175
• Chanan-Khan AA, Kaufman JL, Mehta J, Richardson PG, Miller KC, Lonial S, Munshi NC, Schlossman R, Tariman J, Singhal S.Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.Blood. 200
  17138816
• Richardson PG, Hideshima T, Mitsiades C, Anderson KC.The emerging role of novel therapies for the treatment of relapsed myeloma.J Natl Compr Canc Netw. 2007 Feb;5(2):149-62. Review.
  17335684
• Yasui H, Hideshima T, Ikeda H, Ocio EM, Kiziltepe T, Vallet S, Okawa Y, Neri P, Sukhdeo K, Podar K, Chauhan D, Richardson PG, Raje N, Carrasco DR, Anderson KC.Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associa
  17268521
• Koreth J, Cutler CS, Djulbegovic B, Behl R, Schlossman RL, Munshi NC, Richardson PG, Anderson KC, Soiffer RJ, Alyea EP.High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review a
  17241924
• Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S, Koenig E, Fergus A, Huang Y, Richardson P, Trepicchio WL, Broyl A, Sonneveld P, Shaughnessy JD, Bergsagel PL, Schenkein D, Esseltine DL, Boral A, Anderson KC.Gene expression profiling and correl
  17185464
• Yasui H, Hideshima T, Ikeda H, Jin J, Ocio EM, Kiziltepe T, Okawa Y, Vallet S, Podar K, Ishitsuka K, Richardson PG, Pargellis C, Moss N, Raje N, Anderson KC.BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and
  17173546
• Jagannath S, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Cowan JM, Anderson KC.Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials.Leukemia. 2007 Jan;21
  17096017
• Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M, Schlossman RL, Rajkumar SV, Desikan KR, Hideshima T, Munshi NC, Kelly-Colson K, Doss D, McKenney ML, Gorelik S, Warren D, Freeman A, Rich R, Wu A, Olesnyckyj M, Wride K, Dalton WS
  16840727
• Jagannath S, Richardson PG, Barlogie B, Berenson JR, Singhal S, Irwin D, Srkalovic G, Schenkein DP, Esseltine DL, Anderson KC,.Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with
  16818280
• Tai YT, Li XF, Breitkreutz I, Song W, Neri P, Catley L, Podar K, Hideshima T, Chauhan D, Raje N, Schlossman R, Richardson P, Munshi NC, Anderson KC.Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow
  16818641
• Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA.Frequency, charac
  16754936
• Mitsiades CS, Richardson PG, Anderson KC.The theraputic use of vitamin K compounds in multiple myeloma.Haematologica. 2006 May;91(5):578b.
  16670056
• Richardson PG, Schlossman R, Hideshima T, Anderson KC.New treatments for multiple myeloma.Oncology (Huntingt). 2005 Dec;19(14):1781-92; discussion 1792,. Review.
  16506632
• Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin DH, Rajkumar SV, Srkalovic G, Alsina M, Anderson KC.Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial.Ca
  16470606
• Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Kung AL, Davies FE, Morgan G, Akiyama M, Shringarpure R, Munshi NC, Richardson PG, Hideshima T, Chauhan D, Gu X, Bailey C, Joseph M, Libermann TA, Rosen NS, Anderson KC.Anti-myeloma activity of heat shoc
  16234364
• Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C, Podar K, Munshi NC, Chauhan D, Richardson PG, Anderson KC.Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple
  16418332
• Richardson PG, Mitsiades C, Hideshima T, Anderson KC.Bortezomib: proteasome inhibition as an effective anticancer therapy.Annu Rev Med. 2006;57:33-47. Review.
  16409135
• Roccaro AM, Hideshima T, Raje N, Kumar S, Ishitsuka K, Yasui H, Shiraishi N, Ribatti D, Nico B, Vacca A, Dammacco F, Richardson PG, Anderson KC.Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.C
  16397231
• Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, Mitsiades C, Mitsiades N, Yasui H, Letai A, Ovaa H, Berkers C, Nicholson B, Chao TH, Neuteboom ST, Richardson P, Palladino MA, Anderson KC.A novel orally active proteasome inhibitor induces apop
  16286248
• Richardson PG, Mitsiades CS, Hideshima T, Anderson KC.Novel biological therapies for the treatment of multiple myeloma.Best Pract Res Clin Haematol. 2005;18(4):619-34.
  16026741
• Tai YT, Li X, Tong X, Santos D, Otsuki T, Catley L, Tournilhac O, Podar K, Hideshima T, Schlossman R, Richardson P, Munshi NC, Luqman M, Anderson KC.Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma
  15994968
• Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Blade J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson K
  15958804
• Gribben JG, Ryan DP, Boyajian R, Urban RG, Hedley ML, Beach K, Nealon P, Matulonis U, Campos S, Gilligan TD, Richardson PG, Marshall B, Neuberg D, Nadler LM.Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and res
  15958627
• Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL, Anderson KC.Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):856
  15937109
• Craiu A, Saito Y, Limon A, Eppich HM, Olson DP, Rodrigues N, Adams GB, Dombkowski D, Richardson P, Schlossman R, Choi PS, Grogins J, O'Connor PG, Cohen K, Attar EC, Freshman J, Rich R, Mangano JA, Gribben JG, Anderson KC, Scadden DT.Flowing cells thro
  15292069
• Rajkumar SV, Richardson PG, Hideshima T, Anderson KC.Proteasome inhibition as a novel therapeutic target in human cancer.J Clin Oncol. 2005 Jan 20;23(3):630-9.
  15659509
• Richardson PG, Mitsiades C, Hideshima T, Anderson KC.Proteasome inhibition in the treatment of cancer.Cell Cycle. 2005 Feb;4(2):290-6.
  15655370
• Hayashi T, Hideshima T, Akiyama M, Podar K, Yasui H, Raje N, Kumar S, Chauhan D, Treon SP, Richardson P, Anderson KC.Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.Br J Haematol. 2005 Jan;128(2):192
  15638853
• Lee SJ, Loberiza FR, Antin JH, Kirkpatrick T, Prokop L, Alyea EP, Cutler C, Ho VT, Richardson PG, Schlossman RL, Fisher DC, Logan B, Soiffer RJ.Routine screening for psychosocial distress following hematopoietic stem cell transplantation.Bone Marrow Trans
  15502851
• Le Gouill S, Podar K, Amiot M, Hideshima T, Chauhan D, Itshitsuka K, Kumar S, Raje N, Richardson PG, Harousseau JL, Anderson KC.VEGF induces MCL-1 upregulation and protects multiple myeloma cells against apoptosis.Blood. 2004 Nov 1;104(9):2886-92.
  15217829
• Tai YT, Catley LP, Mitsiades CS, Burger R, Podar K, Shringpaure R, Hideshima T, Chauhan D, Hamasaki M, Ishitsuka K, Richardson P, Treon SP, Munshi NC, Anderson KC.Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human mu
  15087402
• Raje N, Hideshima T, Davies FE, Chauhan D, Treon SP, Young G, Tai YT, Avigan D, Gong J, Schlossman RL, Richardson P, Kufe DW, Anderson KC.Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma.Br J Haematol. 2004 May;125(3):343-
  15086415
• Chauhan D, Li G, Podar K, Hideshima T, Shringarpure R, Catley L, Mitsiades C, Munshi N, Tai YT, Suh N, Gribble GW, Honda T, Schlossman R, Richardson P, Sporn MB, Anderson KC.The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synerg
  15070698
• Hideshima T, Richardson PG, Anderson KC.Targeting proteasome inhibition in hematologic malignancies.Rev Clin Exp Hematol. 2003 Jun;7(2):191-204.
  14763162
• Hideshima T, Chauhan D, Hayashi T, Podar K, Akiyama M, Mitsiades C, MItsiades N, Gong B, Bonham L, de Vries P, Munshi N, Richardson PG, Singer JW, Anderson KC.Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of ag
  14679006
• Alyea E, Weller E, Schlossman R, Canning C, Mauch P, Ng A, Fisher D, Gribben J, Freeman A, Parikh B, Richardson P, Soiffer R, Ritz J, Anderson KC.Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact
  14647268
• Podar K, Catley LP, Tai YT, Shringarpure R, Carvalho P, Hayashi T, Burger R, Schlossman RL, Richardson PG, Pandite LN, Kumar R, Hideshima T, Chauhan D, Anderson KC.GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple
  14644994
• Hideshima T, Chauhan D, Hayashi T, Akiyama M, Mitsiades N, Mitsiades C, Podar K, Munshi NC, Richardson PG, Anderson KC.Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myelom
  14627979
• Richardson PG, Hideshima T, Anderson KC.Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers.Cancer Control. 2003 Sep-Oct;10(5):361-9.
  14581890
• Akiyama M, Hideshima T, Shammas MA, Hayashi T, Hamasaki M, Tai YT, Richardson P, Gryaznov S, Munshi NC, Anderson KC.Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells.Canc
  14559802
• Tai YT, Podar K, Catley L, Tseng YH, Akiyama M, Shringarpure R, Burger R, Hideshima T, Chauhan D, Mitsiades N, Richardson P, Munshi NC, Kahn CR, Mitsiades C, Anderson KC.Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma
  14522909
• LeBlanc R, Hideshima T, Catley LP, Shringarpure R, Burger R, Mitsiades N, Mitsiades C, Cheema P, Chauhan D, Richardson PG, Anderson KC, Munshi NC.Immunomodulatory drug costimulates T cells via the B7-CD28 pathway.Blood. 2004 Mar 1;103(5):1787-90.
  14512311
• Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC.A phase
  12826635
• Catley L, Weisberg E, Tai YT, Atadja P, Remiszewski S, Hideshima T, Mitsiades N, Shringarpure R, LeBlanc R, Chauhan D, Munshi NC, Schlossman R, Richardson P, Griffin J, Anderson KC.NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significan
  12816865
• Maecker B, Anderson KS, von Bergwelt-Baildon MS, Weller E, Vonderheide RH, Richardson PG, Schlossman RL, Menezes IA, Xia Z, Munshi NC, Anderson KC, Nadler LM, Schultze JL.Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma.Br J H
  12786794
• Hayashi T, Treon SP, Hideshima T, Tai YT, Akiyama M, Richardson P, Chauhan D, Grewal IS, Anderson KC.Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells.Br J
  12752100
• Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V, Alyea EP, Antin JH, Stone RM, Soiffer RJ, DeAngelo DJ.Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allog
  12738663
• Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G, Schlossman R, Chauhan D, Munshi NC, Hideshima T, Richon VM, Marks PA, Anderson KC.Molecular sequelae of histone deacetylase inhibition in human malignant B cells.Blood. 2003 Ma
  12531799
• Akiyama M, Hideshima T, Hayashi T, Tai YT, Mitsiades CS, Mitsiades N, Chauhan D, Richardson P, Munshi NC, Anderson KC.Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein.
  12517770
• Hayashi T, Hideshima T, Akiyama M, Richardson P, Schlossman RL, Chauhan D, Munshi NC, Waxman S, Anderson KC.Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment.Mol Cancer Ther. 2002 Aug;1(10):851-60.
  12492118
• Chauhan D, Li G, Auclair D, Hideshima T, Richardson P, Podar K, Mitsiades N, Mitsiades C, Li C, Kim RS, Munshi N, Chen LB, Wong W, Anderson KC.Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide a
  12480690
• Hideshima T, Chauhan D, Hayashi T, Podar K, Akiyama M, Gupta D, Richardson P, Munshi N, Anderson KC.The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma.Mol Cancer Ther. 2002 May;1(7):539-44.
  12479272
• Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Schlossman R, Munshi NC, Hideshima T, Anderson KC.The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cel
  12424198
• Richardson PG, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt D, Elias AD, Antin JH, Soiffer R, Spitzer T, Avigan D, Bearman SI, Martin PL, Kurtzberg J, Vredenburgh J, Chen AR, Arai S, Vogelsang G, McDonald GB, Guinan EC.Multi-institutional use of de
  12393437
• Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P, Schlossman R, Podar K, Munshi NC, Mitsiades N, Anderson KC.Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.Blood. 2003 Feb 15;101(4):1530-4.
  12393500
• Hideshima T, Akiyama M, Hayashi T, Richardson P, Schlossman R, Chauhan D, Anderson KC.Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu.Blood. 2003 Jan 15;101(2):703-5.
  12393542
• Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP, Munshi NC, Richardson PG, Hideshima T, Anderson KC.Molecular sequelae of proteasome inhibition in human multiple myeloma cells.Proc Natl Acad
  12391322
• Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, LeBlanc R, Catley LP, Doss D, Kelly K, McKenney M, Mechlowicz J, Freeman A, Deocampo R, Rich R, Ryoo JJ, Chauhan D, Balinski K, Zeldis J, Anderson KC.Immunomodulatory drug CC-5013
  12384400
• Lin B, Podar K, Gupta D, Tai YT, Li S, Weller E, Hideshima T, Lentzsch S, Davies F, Li C, Weisberg E, Schlossman RL, Richardson PG, Griffin JD, Wood J, Munshi NC, Anderson KC.The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787
  12208756
• LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, Neuberg D, Goloubeva O, Pien CS, Adams J, Gupta D, Richardson PG, Munshi NC, Anderson KC.Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival
  12208752
• Chauhan D, Catley L, Hideshima T, Li G, Leblanc R, Gupta D, Sattler M, Richardson P, Schlossman RL, Podar K, Weller E, Munshi N, Anderson KC.2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells.Blood. 2002 Sep 15;100(6):2187-94.
  12200384
• Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, Anderson KC.Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human m
  12173037
• Elias AD, Skarin AT, Richardson P, Ibrahim J, McCauley M, Frei E.Dose-intensive therapy for extensive-stage small cell lung cancer and extrapulmonary small cell carcinoma: long-term outcome.Biol Blood Marrow Transplant. 2002;8(6):326-33.
  12108918
• Akiyama M, Hideshima T, Hayashi T, Tai YT, Mitsiades CS, Mitsiades N, Chauhan D, Richardson P, Munshi NC, Anderson KC.Cytokines modulate telomerase activity in a human multiple myeloma cell line.Cancer Res. 2002 Jul 1;62(13):3876-82.
  12097303
• Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi NC, Treon SP, Anderson KC.Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.Blood. 2002 Jun 15;
  12036884
• Elias AD, Ibrahim J, Richardson P, Avigan D, Joyce R, Reich E, McCauley M, Wheeler C, Frei E.The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemot
  12017145
• Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi N, Treon SP, Anderson KC.Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications.Blood. 2002 Jun 1;99(11):4079-86.
  12010810
• Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, Adams J, Anderson KC.NF-kappa B as a therapeutic target in multiple myeloma.J Biol Chem. 2002 May 10;277(19):16639-47.
  11872748
• Chauhan D, Auclair D, Robinson EK, Hideshima T, Li G, Podar K, Gupta D, Richardson P, Schlossman RL, Krett N, Chen LB, Munshi NC, Anderson KC.Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays.Oncogen
  11857078
• Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, Lin B, Lentzsch S, Davies FE, Chauhan D, Schlossman RL, Richardson P, Ralph P, Wu L, Payvandi F, Muller G, Stirling DI, Anderson KC.Adherence of multiple myeloma cells to bone marrow stromal cells
  11753617
• Hideshima T, Chauhan D, Podar K, Schlossman RL, Richardson P, Anderson KC.Novel therapies targeting the myeloma cell and its bone marrow microenvironment.Semin Oncol. 2001 Dec;28(6):607-12.
  11740818
• Elias AD, Richardson P, Avigan D, Ibrahim J, Joyce R, McDermott D, Levine J, Warren D, McCauley M, Wheeler C, Frei E.A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive met
  11593317
• Richardson PG.Basilar artery thrombosis.Emerg Med (Fremantle). 2001 Sep;13(3):367-72.
  11554871
• Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC.The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications.Oncogene. 2001 Jul 27;20(33):4519-27.
  11494147
• Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R, Hideshima T, Anderson KC.TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications.Blood. 2001 Aug 1;98(3):795-804
  11468181
• Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, Hideshima T, Lin BK, Gupta D, Shima Y, Chauhan D, Mitsiades C, Raje N, Richardson P, Anderson KC.Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and m
  11435313
• Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, Lin B, Podar K, Gupta D, Chauhan D, Treon SP, Richardson PG, Schlossman RL, Morgan GJ, Muller GW, Stirling DI, Anderson KC.Thalidomide and immunomodulatory derivatives augment natural killer cel
  11418482
• Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP.Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing m
  11352965
• Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC.The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.Cancer Res. 2001 Apr 1;61(7):3071-6.
  11306489
• Elias AD, Richardson P, Avigan D, Ibrahim J, Joyce R, Demetri G, Levine J, Warren D, Arthur T, Reich E, Wheele C, Frei E, Ayash L.A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemother
  11277174
• Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT, Treon SP, Lin B, Schlossman RL, Richardson P, Muller G, Stirling DI, Anderson KC.Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.Blood
  11049970
• Avigan D, Wu Z, Joyce R, Elias A, Richardson P, McDermott D, Levine J, Kennedy L, Giallombardo N, Hurley D, Gong J, Kufe D.Immune reconstitution following high-dose chemotherapy with stem cell rescue in patients with advanced breast cancer.Bone Marrow Tra
  10918427
• Kraeft SK, Sutherland R, Gravelin L, Hu GH, Ferland LH, Richardson P, Elias A, Chen LB.Detection and analysis of cancer cells in blood and bone marrow using a rare event imaging system.Clin Cancer Res. 2000 Feb;6(2):434-42.
  10690521
• Richardson P, Guinan E.The pathology, diagnosis, and treatment of hepatic veno-occlusive disease: current status and novel approaches.Br J Haematol. 1999 Dec;107(3):485-93.
  10583247
• Elias A, Ibrahim J, Skarin AT, Wheeler C, McCauley M, Ayash L, Richardson P, Schnipper L, Antman KH, Frei E.Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome.J Clin Oncol. 1999 Apr;17(4):1175.
  10561176
• Frei E, Richardson P, Avigan D, Bunnell C, Wheeler C, Elias A.The interval between courses of high-dose chemotherapy with stem cell rescue: therapeutic hypotheses.Bone Marrow Transplant. 1999 Nov;24(9):939-45.
  10556951
• Frei E, Elias A, Wheeler C, Richardson P, Hryniuk W.The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity.Clin Cancer Res. 1998 Sep;4(9):2027-37.
  9748116